What is Skye Bioscience's earnings per share (EPS)?

Skye Bioscience (SKYE) reported diluted earnings per share of $-1.41 for fiscal year 2025. This represents a -93.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Skye Bioscience Financials

SKYE

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Skye Bioscience (SKYE) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

1/9

Skye Bioscience passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

0.77x

For every $1 of reported earnings, Skye Bioscience generates $0.77 in operating cash flow (-$43.1M OCF vs -$55.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$57.4M

YoY-92.1%

Skye Bioscience's EBITDA was -$57.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 92.1% from the prior year.

Net Income

-$55.9M

YoY-110.5%

Skye Bioscience reported -$55.9M in net income in fiscal year 2025. This represents a decrease of 110.5% from the prior year.

EPS (Diluted)

$-1.41

YoY-93.2%

Skye Bioscience earned $-1.41 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 93.2% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$43.1M

YoY-60.5%

Skye Bioscience generated -$43.1M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 60.5% from the prior year.

Cash & Debt

$5.9M

YoY-91.4%

5Y CAGR+19.0%

10Y CAGR+6.2%

Skye Bioscience held $5.9M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

33M

YoY+7.8%

Skye Bioscience had 33M shares outstanding in fiscal year 2025. This represents an increase of 7.8% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-279.3%

YoY-240.3pp

5Y CAGR+1176.1pp

Skye Bioscience's ROE was -279.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 240.3 percentage points from the prior year.

Capital Allocation

R&D Spending

$42.4M

YoY+126.5%

5Y CAGR+85.2%

10Y CAGR+53.7%

Skye Bioscience invested $42.4M in research and development in fiscal year 2025. This represents an increase of 126.5% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$6K

YoY-99.6%

5Y CAGR-2.7%

10Y CAGR+12.3%

Skye Bioscience invested $6K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 99.6% from the prior year.

SKYE Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$42.4M+126.5%	$18.7M+221.4%	$5.8M-3.2%	$6.0M+105.1%	$2.9M+50.8%	$1.9M
SG&A Expenses	$15.8M-10.9%	$17.7M+125.7%	$7.9M+28.8%	$6.1M+24.0%	$4.9M+13.2%	$4.3M
Operating Income	-$58.2M-92.6%	-$30.2M+13.1%	-$34.7M-89.7%	-$18.3M-133.3%	-$7.8M-24.8%	-$6.3M
Interest Expense	$0-100.0%	$749K-17.3%	$906K+36.3%	$665K-13.5%	$769K+8.9%	$706K
Income Tax	$5K-46.4%	$10K+179.8%	$4K-46.6%	$7K+221.0%	$2K+31.3%	$2K
Net Income	-$55.9M-110.5%	-$26.6M+29.4%	-$37.6M-93.2%	-$19.5M-128.6%	-$8.5M-29.9%	-$6.6M
EPS (Diluted)	$-1.41-93.2%	$-0.73+86.4%	$-5.37	$-8.77	$-0.02+33.3%	$-0.03

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$9.4M-34.7%	$14.3M+99.2%	$7.2M	N/A	$4.9M+19.7%	$4.1M+109.5%	$1.9M
SG&A Expenses	N/A	$3.9M0.0%	$3.9M-14.4%	$4.6M	N/A	$4.6M+7.2%	$4.3M+2.9%	$4.2M
Operating Income	N/A	-$13.3M+27.3%	-$18.2M-55.1%	-$11.8M	N/A	-$5.0M+40.9%	-$8.4M-36.6%	-$6.2M
Interest Expense	N/A	$0	$0-100.0%	$1K	N/A	-$91K-120.2%	$450K+3.0%	$437K
Income Tax	N/A	$0-100.0%	$3K+70.0%	$2K	N/A	$0-100.0%	$8K+303.6%	$2K
Net Income	N/A	-$12.8M+27.6%	-$17.6M-58.7%	-$11.1M	N/A	-$3.9M+50.7%	-$7.9M-57.4%	-$5.0M
EPS (Diluted)	N/A	$-0.32+27.3%	$-0.44-57.1%	$-0.28	N/A	$-0.10+50.0%	$-0.20-11.1%	$-0.18

SKYE Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$28.3M-61.1%	$72.8M+509.4%	$11.9M+31.1%	$9.1M-7.5%	$9.9M+268.9%	$2.7M
Current Assets	$27.1M-61.7%	$70.8M+507.9%	$11.7M+30.3%	$8.9M-7.0%	$9.6M+260.8%	$2.7M
Cash & Equivalents	$5.9M-91.4%	$68.4M+5345.1%	$1.3M+1.0%	$1.2M-86.1%	$9.0M+263.8%	$2.5M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$8.3M+79.7%	$4.6M-67.2%	$14.1M+16.1%	$12.1M+203.7%	$4.0M+79.7%	$2.2M
Current Liabilities	$8.2M+89.1%	$4.3M-68.8%	$13.9M+14.7%	$12.1M+209.8%	$3.9M+397.0%	$787K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$20.0M-70.6%	$68.2M+3296.9%	-$2.1M+29.1%	-$3.0M-151.3%	$5.9M+1200.9%	$451K
Retained Earnings	-$186.9M-42.7%	-$130.9M-25.5%	-$104.4M-56.4%	-$66.7M-41.2%	-$47.3M-22.0%	-$38.7M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$28.3M-31.5%	$41.3M-20.8%	$52.2M-19.5%	$64.8M-11.0%	$72.8M-10.8%	$81.5M-6.6%	$87.3M-8.0%	$94.8M
Current Assets	$27.1M-32.1%	$39.9M-21.1%	$50.6M-19.7%	$63.0M-11.0%	$70.8M-11.3%	$79.8M-8.3%	$87.0M-8.0%	$94.6M
Cash & Equivalents	$5.9M-68.1%	$18.4M-22.6%	$23.8M-48.6%	$46.4M-32.1%	$68.4M+1.5%	$67.4M-9.1%	$74.1M-11.1%	$83.3M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$8.3M-2.3%	$8.5M0.0%	$8.5M+53.1%	$5.5M+20.2%	$4.6M-19.5%	$5.7M-60.3%	$14.5M-9.4%	$16.0M
Current Liabilities	$8.2M-1.9%	$8.4M+0.7%	$8.3M+56.3%	$5.3M+22.6%	$4.3M-22.9%	$5.6M-60.7%	$14.3M-9.4%	$15.8M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$20.0M-39.0%	$32.8M-24.8%	$43.7M-26.3%	$59.3M-13.1%	$68.2M-10.1%	$75.8M+4.1%	$72.8M-7.7%	$78.9M
Retained Earnings	-$186.9M-8.4%	-$172.4M-8.0%	-$159.7M-12.4%	-$142.1M-8.5%	-$130.9M-8.0%	-$121.2M-3.3%	-$117.3M-7.2%	-$109.4M

SKYE Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$43.1M-70.6%	-$25.2M-80.9%	-$14.0M-9.5%	-$12.7M-96.8%	-$6.5M-6.9%	-$6.1M
Capital Expenditures	$6K-99.6%	$1.6M+12681.1%	$13K-55.3%	$28K-69.1%	$91K+1156.8%	$7K
Free Cash Flow	-$43.1M-60.5%	-$26.8M-92.2%	-$14.0M-9.3%	-$12.8M-94.5%	-$6.6M-8.3%	-$6.1M
Investing Cash Flow	-$19.5M-7839.4%	-$246K-103.7%	$6.6M+26.5%	$5.2M+5838.6%	-$91K-1156.8%	-$7K
Financing Cash Flow	$30K-100.0%	$83.6M+408.2%	$16.4M+7975.4%	-$209K-101.6%	$13.1M+95.2%	$6.7M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	-$9.8M+26.9%	-$13.4M-24.4%	-$10.7M-17.0%	-$9.2M-12.4%	-$8.2M-55.3%	-$5.3M+25.8%	-$7.1M-50.7%	-$4.7M
Capital Expenditures	$0	$0	$0-100.0%	$6K-87.4%	$50K-96.7%	$1.5M+4577.2%	$32K+920.5%	$3K
Free Cash Flow	-$9.8M+26.9%	-$13.4M-24.4%	-$10.7M-16.9%	-$9.2M-11.8%	-$8.2M-21.3%	-$6.8M+4.8%	-$7.1M-51.3%	-$4.7M
Investing Cash Flow	-$2.8M-135.2%	$8.0M+167.2%	-$11.9M+7.4%	-$12.8M-14267.6%	$90K+106.3%	-$1.4M-4352.8%	-$32K-102.8%	$1.1M
Financing Cash Flow	$11K	$0-100.0%	$18K	$0-100.0%	$6K	$0+100.0%	-$2.1M-102.4%	$85.7M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

SKYE Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-279.3%-240.3pp	-39.0%	N/A	N/A	-145.3%+1310.1pp	-1455.4%
Return on Assets	-197.5%-161.0pp	-36.5%+278.8pp	-315.3%-101.4pp	-213.8%-127.3pp	-86.5%+159.1pp	-245.6%
Current Ratio	3.30-13.0	16.32+15.5	0.84+0.1	0.74-1.7	2.46-0.9	3.38
Debt-to-Equity	0.41+0.3	0.07+6.7	-6.60-2.6	-4.03-4.7	0.68-4.2	4.93
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	-38.8%+1.5pp	-40.4%-21.6pp	-18.7%	N/A	-5.1%+5.7pp	-10.8%-4.5pp	-6.4%
Return on Assets	N/A	-30.9%+2.9pp	-33.8%-16.6pp	-17.1%	N/A	-4.8%+4.3pp	-9.1%-3.8pp	-5.3%
Current Ratio	3.30-1.5	4.77-1.3	6.09-5.8	11.85-4.5	16.32+2.1	14.19+8.1	6.07+0.1	5.99
Debt-to-Equity	0.41+0.2	0.26+0.1	0.19+0.1	0.09+0.0	0.070.0	0.08-0.1	0.200.0	0.20
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Avalo Therapeutics Inc AVTX

$370.8M

Cardiff Oncology Inc CRDF

$108.0M

Zura Bio Limited ZURA

$575.0M

Forte Biosciences Inc FBRX

$367.1M

TuHURA Biosciences HURA

$92.2M

Frequently Asked Questions

Is Skye Bioscience profitable?

No, Skye Bioscience (SKYE) reported a net income of -$55.9M in fiscal year 2025.

What is Skye Bioscience's EBITDA?

Skye Bioscience (SKYE) had EBITDA of -$57.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Skye Bioscience's return on equity (ROE)?

Skye Bioscience (SKYE) has a return on equity of -279.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Skye Bioscience's free cash flow?

Skye Bioscience (SKYE) generated -$43.1M in free cash flow during fiscal year 2025. This represents a -60.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Skye Bioscience's operating cash flow?

Skye Bioscience (SKYE) generated -$43.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Skye Bioscience's total assets?

Skye Bioscience (SKYE) had $28.3M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Skye Bioscience's capital expenditures?

Skye Bioscience (SKYE) invested $6K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Skye Bioscience spend on research and development?

Skye Bioscience (SKYE) invested $42.4M in research and development during fiscal year 2025.

How many shares does Skye Bioscience have outstanding?

Skye Bioscience (SKYE) had 33M shares outstanding as of fiscal year 2025.

What is Skye Bioscience's current ratio?

Skye Bioscience (SKYE) had a current ratio of 3.30 as of fiscal year 2025, which is generally considered healthy.

What is Skye Bioscience's debt-to-equity ratio?

Skye Bioscience (SKYE) had a debt-to-equity ratio of 0.41 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Skye Bioscience's return on assets (ROA)?

Skye Bioscience (SKYE) had a return on assets of -197.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Skye Bioscience's cash runway?

Based on fiscal year 2025 data, Skye Bioscience (SKYE) had $5.9M in cash against an annual operating cash burn of $43.1M. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Skye Bioscience's Piotroski F-Score?

Skye Bioscience (SKYE) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Skye Bioscience's earnings high quality?

Skye Bioscience (SKYE) has an earnings quality ratio of 0.77x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.